In Vivo Real-Time Imaging of Extracellular Vesicles in Liver Regeneration via Aggregation-Induced Emission Luminogens
- 7 March 2019
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 13 (3), 3522-3533
- https://doi.org/10.1021/acsnano.8b09776
Abstract
Extracellular vesicles (EVs) attract much attention in liver pathology because they regulate cell-cell communication and a lot of pathophysiological events via transferring their cargos. Monitoring and understanding the in vivo fate and therapeutic capacity of these EVs is critical for the development and optimization of EV-based diagnosis and therapy. Herein, we demonstrate the use of an aggregation-induced emission luminogen (AIEgen), DPA-SCP, for the real-time tracking of EVs derived from human placenta-derived mesenchymal stem cells (hP-MSCs) and their therapeutic effects in a mouse acute liver injury (ALI) model. In vitro, DPA-SCP does not alter the inherent characteristics of MSC-derived EVs and shows extremely low toxicity. Moreover, DPA-SCP exhibited superior labeling efficiency and tracking capability to the most popular commercial EV trackers, PKH26 and DiI. In vivo, DPA-SCP precisely and quantitatively tracked the behaviors of EVs for 7 days in the mouse ALI model without influencing their regenerative capacity and therapeutic efficacy. The therapeutic effects of EVs may attribute to their ability for reducing inflammatory cell infiltration, enhancing cell survival and antiapoptotic effects. In conclusion, DPA-SCP with an AIE signature serves as a favorable and safe tracker for in vivo real-time imaging of EVs in liver regeneration.Keywords
Funding Information
- National Natural Science Foundation of China (81501528, 81671734)
- Ministry of Science and Technology of the People's Republic of China (2017YFA0103201)
This publication has 52 references indexed in Scilit:
- Trends in premature mortality in the USA by sex, race, and ethnicity from 1999 to 2014: an analysis of death certificate dataThe Lancet, 2017
- New metrics for the Lancet Standing Commission on Liver Disease in the UKThe Lancet, 2016
- Transplantation with autologous bone marrow‐derived mesenchymal stem cells for alcoholic cirrhosis: Phase 2 trialHepatology, 2016
- Liver transplantation: history, outcomes and perspectivesEinstein (São Paulo), 2015
- Clinical Therapeutic Effects of Human Umbilical Cord–Derived Mesenchymal Stem Cells Transplantation in the Treatment of End-Stage Liver DiseaseTransplantation Proceedings, 2015
- Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysisBMC Medicine, 2014
- Peripheral vein infusion of autologous mesenchymal stem cells in Egyptian HCV-positive patients with end-stage liver diseaseStem Cell Research & Therapy, 2014
- Immunosuppression minimization vs. complete drug withdrawal in liver transplantationJournal of Hepatology, 2013
- Critical Review of Clinical Trials of Bone Marrow Stem Cells in Liver DiseaseGastroenterology, 2008
- Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interactionHaematologica, 2007